Biomarker ID | 1178 |
PMID | 23896625 |
Year | 2013 |
Biomarker | SLCO2B1 rs12422149 (GG allele) |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: [0.589 (95% CI: 0.37–0.95)] |
Effect on Pathways | Pathways include: Transport of organic anions, Transport of vitamins, nucleosides, and related molecules, SLC-mediated transmembrane transport, Oncostatin M, Transmembrane transport of small molecules |
Experiment | Time to Progression |
Type of Biomarker | Prognostic |
Cohort | 87 patients with Prostate Cancer were included in the study. Of the 87 patients, 76 progressed to CRPC and 53 died during the median follow-up duration of 39.5 months. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p =0.028 |
Method Used | PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |